The biotech sector has always held a special appeal for risk-tolerant investors. While these companies face high overhead in the form of towering R&D costs and long lead times for bringing new ...

Biotech investors are once again rotating aggressively into clinical-stage growth stories as a fresh wave of capital ...

Structure Therapeutics advances oral therapies for chronic diseases, with a pipeline focused on metabolic and pulmonary ...

This biotechnology firm develops clinical-stage therapies for autoimmune and neuroinflammatory diseases using proprietary TYK2 inhibitors.

One day in early May, web-based prediction market platform Kalshi listed two contracts tied to Compass Pathways’ psilocybin ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

This multiple sclerosis treatment stock is in a handle of a long cup base. It recently raised its 2026 revenue forecast.

Biotech has been pulling off some remarkable science of late, while M&A and IPOs return to bolster the sector. But that doesn ...

Zymeworks is transitioning into an oncology royalty platform with a robust internal discovery engine. Click here to read an ...

Inovio Pharmaceuticals and Novavax stocks pare back earlier gains as the rally loses enthusiasm. Following a robust rally, Moderna appears to be regaining leadership within the biotech space. Inhibrx ...

An Indian woman revealed how she moved past her NEET setback to earn an Ivy League degree and work in biotech.